Covid Vax Maker Moderna Slashes Projected Revenue on Slow Demand
SeekingAlpha: “Moderna (NASDAQ:MRNA) shares plunged 20% premarket on Monday after the biotech firm cut its revenue guidance for 2025 on slow demand for its Covid and RSV vaccines.”
“The company projects revenue in the range of $1.5B to $2.5B for this year, mostly in the second half, which is below its previous estimate of $2.5B to $3.5B.”